Biotech · Private company · Ann Arbor, MI, US
Tsrl, Inc.
Track this companyFree. Adds Tsrl, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards10
- Phase 1 Clinical Trial to Assess the Pharmacokinetics, Safety and Tolerance of a Zanamivir Transdermal System in Healthy SubjectsFiscal year 2026 · $999.3KNIH RePORTER 4U44AI184201-02 · fetched Nov 12, 2026
- Microneedle delivery of Trospium Chloride optimized for improved tolerance and patient outcomes in overactive bladder diseaseFiscal year 2026 · $1.1MNIH RePORTER 5R44DK143799-03 · fetched Nov 12, 2026
- Development of MRS-2541, a methionyl-tRNA synthetase inhibitor, for Gram positive bacterial infections.Fiscal year 2025 · $999.8KNIH RePORTER 5R44AI134190-06 · fetched Nov 12, 2026
- Novel, Self-Applied MicroArray Patch (MAP) of Zanamivir for Treatment of the FluFiscal year 2025 · $1MNIH RePORTER 5R44AI179506-03 · fetched Nov 12, 2026
- Microneedle delivery of Trospium Chloride optimized for improved tolerance and patient outcomes in overactive bladder diseaseFiscal year 2025 · $1.1MNIH RePORTER 9R44DK143799-02A1 · fetched Nov 12, 2026
- Optimized Zanamivir MicroArray Patch (MAP) Formulation for Single Application Treatment of the FluFiscal year 2024 · $299.6KNIH RePORTER 1R43IP001280-01 · fetched Nov 12, 2026
- Phase 1 Clinical Trial to Assess the Pharmacokinetics, Safety and Tolerance of a Zanamivir Transdermal System in Healthy SubjectsFiscal year 2024 · $292.7KNIH RePORTER 1U44AI184201-01 · fetched Nov 12, 2026
- Novel, Self-Applied MicroArray Patch (MAP) of Zanamivir for Treatment of the FluFiscal year 2024 · $999.7KNIH RePORTER 4R44AI179506-02 · fetched Nov 12, 2026
- Microneedle Delivery of Zanamivir for the Treatment of Influenza InfectionsFiscal year 2024 · $998.7KNIH RePORTER 5R44AI129122-08 · fetched Nov 12, 2026
- Development of MRS-2541, a methionyl-tRNA synthetase inhibitor, for Gram positive bacterial infections.Fiscal year 2024 · $997.7KNIH RePORTER 5R44AI134190-05 · fetched Nov 12, 2026